Mediolanum International Funds Ltd Invests $1.24 Million in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Mediolanum International Funds Ltd acquired a new position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 18,939 shares of the biotechnology company's stock, valued at approximately $1,237,000.

Other large investors have also made changes to their positions in the company. Merit Financial Group LLC acquired a new position in shares of BioMarin Pharmaceutical during the fourth quarter valued at about $317,000. Assenagon Asset Management S.A. raised its holdings in BioMarin Pharmaceutical by 461.3% in the 4th quarter. Assenagon Asset Management S.A. now owns 611,667 shares of the biotechnology company's stock valued at $40,205,000 after acquiring an additional 502,695 shares in the last quarter. Wedmont Private Capital bought a new stake in shares of BioMarin Pharmaceutical in the 4th quarter worth approximately $430,000. Swedbank AB grew its holdings in shares of BioMarin Pharmaceutical by 11.2% during the 4th quarter. Swedbank AB now owns 432,122 shares of the biotechnology company's stock worth $28,403,000 after purchasing an additional 43,593 shares in the last quarter. Finally, EULAV Asset Management increased its position in shares of BioMarin Pharmaceutical by 12.9% during the third quarter. EULAV Asset Management now owns 131,000 shares of the biotechnology company's stock valued at $9,208,000 after purchasing an additional 15,000 shares during the period. Institutional investors and hedge funds own 98.71% of the company's stock.

Insider Transactions at BioMarin Pharmaceutical

In other news, EVP Charles Greg Guyer sold 5,278 shares of the stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $66.37, for a total value of $350,300.86. Following the transaction, the executive vice president now owns 68,909 shares of the company's stock, valued at $4,573,490.33. This represents a 7.11 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.85% of the stock is currently owned by corporate insiders.

BioMarin Pharmaceutical Trading Up 0.2 %

NASDAQ:BMRN traded up $0.16 during trading hours on Thursday, hitting $64.34. 1,143,559 shares of the stock were exchanged, compared to its average volume of 1,627,132. The company's 50 day moving average is $65.04 and its two-hundred day moving average is $72.46. The company has a market capitalization of $12.26 billion, a P/E ratio of 38.53, a price-to-earnings-growth ratio of 0.55 and a beta of 0.28. BioMarin Pharmaceutical Inc. has a twelve month low of $60.63 and a twelve month high of $94.85. The company has a quick ratio of 2.62, a current ratio of 4.27 and a debt-to-equity ratio of 0.11.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on BMRN shares. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $90.00 target price on shares of BioMarin Pharmaceutical in a research report on Thursday, December 12th. William Blair lowered shares of BioMarin Pharmaceutical from an "outperform" rating to a "market perform" rating in a research report on Wednesday, October 30th. Robert W. Baird dropped their price target on shares of BioMarin Pharmaceutical from $72.00 to $65.00 and set a "neutral" rating for the company in a research report on Wednesday, October 30th. Royal Bank of Canada reaffirmed a "sector perform" rating and set a $80.00 price objective on shares of BioMarin Pharmaceutical in a report on Wednesday, October 30th. Finally, Wolfe Research assumed coverage on BioMarin Pharmaceutical in a report on Friday, November 15th. They issued an "outperform" rating and a $95.00 target price for the company. Seven investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, BioMarin Pharmaceutical presently has an average rating of "Moderate Buy" and a consensus target price of $94.20.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.